2022
Cholinergic and dopaminergic‐mediated motivated behavior in healthy states and in substance use and mood disorders
Nunes EJ, Kebede N, Bagdas D, Addy NA. Cholinergic and dopaminergic‐mediated motivated behavior in healthy states and in substance use and mood disorders. Journal Of The Experimental Analysis Of Behavior 2022, 117: 404-419. PMID: 35286712, PMCID: PMC9743782, DOI: 10.1002/jeab.747.Peer-Reviewed Original ResearchMeSH KeywordsCholinergic AgentsDopamineHumansMood DisordersMotivationNucleus AccumbensSubstance-Related DisordersConceptsMood disordersSubstance useActivational componentsMotivated behaviorComorbid substance useMesolimbic dopamine systemDA releaseCholinergic activityCholinergic transmissionImportant neuromodulatorCholinergic dysregulationDA regulationDopamine systemDA signalingActivational aspectsDisease statesDisordersAversive stimuliPossible roleHealthy stateCholinergicAcetylcholineStimuliEtiologyIllness
2020
Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats
Nunes EJ, Rupprecht LE, Foster DJ, Lindsley CW, Conn PJ, Addy NA. Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats. Neuropharmacology 2020, 171: 108089. PMID: 32268153, PMCID: PMC7313677, DOI: 10.1016/j.neuropharm.2020.108089.Peer-Reviewed Original ResearchConceptsSucrose preference testVentral tegmental areaMuscarinic M5 receptorsCholinergic toneM5 receptorsBehavioral effectsFemale ratsDepressive-like behavioral effectsIntra-VTA infusionAnxiogenic-like effectsAcetylcholinesterase inhibitor physostigmineAnxiety-related behaviorVTA administrationCholinergic modulationCholinergic receptorsMuscarinic receptorsInhibitor physostigmineSwim testTegmental areaMale ratsMood disordersVTA infusionsFST behaviorRatsPhysostigmine